A conserved viral peptide for use in cancer immunotherapy
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for viral peptide (CE1)-based therapeutics for HCC prevention and treatment.
Compositions and Methods for Producing Dendritic Cell-based Vaccines with Enhanced Efficacy
Summary:
The National Cancer Institute (NCI) is seeking research co-development partners and/or licensees for NCI’s compositions and methods to enhance the efficacy of dendritic cell (DC)-based cancer vaccines.
Method of Detecting Circulating Cell-Free HPV 6 and 11 DNA in Patients Afflicted With Diseases Caused by Chronic HPV 6 or 11 Infection and Use Thereof
Summary:
The National Cancer Institute (NCI) and Frederick National Laboratory for Cancer Research (FNLCR) seek research co-development partners and/or licensees for commercial development of a novel liquid biopsy diagnostic for non-invasive detection of cell-free HPV 6 and 11 DNA for recurrent respiratory papillomatosis (RRP).
Chimeric VLP vaccines to Prevent HTLV-1 Infection
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection.
T Cell Receptors Targeting HPV 6 or HPV 11
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
Use of Acetalax for Treatment of Triple Negative Breast Cancer
Summary:
NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).
Pyruvate Kinase M2 Activators for the Treatment of Cancer
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics.
Systems and Methods to Automatically Detect Ellipsoid Zone Loss in SD-OCT Imaging
Summary:
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for an automatic deep learning-based algorithm to detect and quantitate ellipsoid zone (EZ) loss in Spectral Domain Optical Coherence Tomography (SD-OCT) images.
Bifunctional Antibody Fusion Molecules for Use in Cancer Immunotherapy
Summary:
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.